Drug profile · INN
remibrutinib
RHAPSIDO
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
remibrutinib (RHAPSIDO) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN remibrutinib
Brand RHAPSIDO
Route ORAL
Formulation TABLET
ATC code L04AA60
Frequently asked questions
What is remibrutinib?
remibrutinib (RHAPSIDO) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for remibrutinib?
RHAPSIDO is a marketed brand name for remibrutinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of remibrutinib?
remibrutinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.